What You Should Know:
– Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced a collaboration with Google Cloud to develop a cutting-edge foundation model for generative small molecule de novo design, propelling Evogene’s ChemPass AI tech-engine to new levels of innovation.
– ChemPass AI is a computational technology platform that directs and accelerates the discovery and development of novel products based on small molecules. This groundbreaking initiative seeks to advance the discovery and development of novel small molecules for drug development, sustainable crop protection, and other innovative products across a wide range of life-science industries.
Evogene and Google Cloud Partnership: Pioneering a Foundation Model for Breakthrough Discoveries in Life Sciences
Evogene is collaborating with Google Cloud to develop a cutting-edge AI foundation model designed to transform the discovery and optimization of small molecules with specific properties. Leveraging Google Cloud’s Vertex AI, GPUs on Google Compute Engine, and Google Cloud Storage, this partnership will provide the extensive computational power and storage needed to train the model on a vast dataset of approximately 40 billion molecular structures. The model aims to expedite the generation and evaluation of potential candidates for innovative life science products with unprecedented speed and accuracy.
This initiative builds on the successful integration of ChemPass AI into Google Cloud, expanding its capabilities to produce and refine novel small molecule structures with targeted attributes. Key advantages of this advanced technology include:
– Accelerated Drug Discovery: The foundation model has the potential to significantly reduce drug development time and costs, while improving the success rate of identifying promising candidates for pharmaceutical applications.
– Sustainable Agricultural Solutions: In agriculture, the model supports the development of novel products to address critical global challenges like food security, crop protection, and resource efficiency.
– Broad Industrial Applications: Beyond pharmaceuticals and agriculture, the model’s ability to design small molecules with specific characteristics opens pathways for sustainable innovations across a variety of industries.
The collaboration between Evogene, a leader in computational predictive biology, and Google Cloud, an AI and machine learning powerhouse, presents compelling opportunities for potential partners in the pharmaceutical and agricultural sectors. By enhancing R&D efforts through ChemPass AI’s generative capabilities, companies can leverage this powerful foundation model to achieve faster, more efficient product development and gain a competitive advantage in their respective industries.
Ofer Haviv, Evogene’s President and CEO stated: “This strategic collaboration underscores Evogene’s commitment to innovation and its position at the forefront of computational predictive biology, utilizing our AI tech-engines. We are proud to be collaborating with Google Cloud, a recognized leader in cloud computing, accelerating our growth trajectory and delivering significant value to our shareholders and partners.”
